Congratulations To

RIBOLIFE (Stock Code: 6938.HK)

On The Successful IPO On The Main board Of The HKEX!

COMPANY PROFILE

Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company’s main business is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.  

(Source: http://www.hkex.com.hk/）

CR SWCS Team is honoured to serve as

RIBOLIFE’s Joint Company Secretary,

committed to ensuring governance,

compliance, and sustained growth.